Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World Effectiveness

RATIONALE & OBJECTIVE: Some US hemodialysis (HD) facilities switched from oral cinacalcet to intravenous etelcalcetide as the primary calcimimetic therapy to control parathyroid hormone (PTH) levels after the introduction of etelcalcetide in 2017. Although clinical trials have demonstrated the s...

Descripción completa

Detalles Bibliográficos
Autores principales: Karaboyas, Angelo, Muenz, Daniel, Hwang, Yunji, Goodman, William, Cheng, Sunfa, Desai, Pooja, Fox, Kathleen M., Robinson, Bruce M., Pisoni, Ronald L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142674/
https://www.ncbi.nlm.nih.gov/pubmed/35637925
http://dx.doi.org/10.1016/j.xkme.2022.100475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142674/
https://www.ncbi.nlm.nih.gov/pubmed/35637925
http://dx.doi.org/10.1016/j.xkme.2022.100475

Ejemplares similares